Other Clinical Trial - Phase 2, Randomized, Double Blind, Placebo

Status Completed

Clinical Trial Summary

This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in patients with ALS .

MSC-NTF cells are a novel cell-therapeutic approach which is expected to effectively deliver Neurotrophic factors, which are potent survival factors for neurons, directly to the site of damage.

Clinical Trial Description

The MSC-NTF cell therapy (NurOwn™) is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patients' own bone marrow, propagated ex vivo and induced to secrete NTFs. The autologous MSC-NTF cells are back-transplanted into the ALS patient into the sites of damage, the spinal cord and the muscles.

NTFs are potent survival factors for embryonic, neonatal, and adult neurons and are considered potential therapeutic candidates for ALS. Delivery of appropriate NTFs to the immediate environment of afflicted neurons in ALS patients is expected to improve their survival and thus slow down disease progression and alleviate symptoms.

Previous open-label clinical trials have shown that MSC-NTF cells treatment was well tolerated and appears to be generally safe. Some initials indications of clinical benefit were also observed in some patients.

This multi-center, randomized, double blind, placebo controlled study will evaluate the safety and efficacy of a single combined intramuscular and intrathecal administration of MSC-NTF cells in early-stage ALS patients. Patients will be followed for approximately three months before transplantation with their autologous MSC-NTF cells or placebo. During this period of time, patient bone-marrow will be harvested and mesenchymal stromal cells will be isolated and expanded. Following treatment patients will be followed for a total of six months at monthly visits. ;

Study Design

Related Conditions & MeSH terms

Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS)
Motor Neuron Disease

Clinical Trial Details

NCT number	NCT02017912
Study type	Interventional
Source	Brainstorm-Cell Therapeutics
Contact
Status	Completed
Phase	Phase 2
Start date	May 2014
Completion date	July 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02365922` - Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Completed	`NCT01699451` - DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida
Completed	`NCT04577404` - Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)	Phase 3
Terminated	`NCT03580616` - Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)	Phase 2
Completed	`NCT01884571` - Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)	Phase 2
Completed	`NCT02118805` - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Completed	`NCT00244244` - A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS	Phase 2
Active, not recruiting	`NCT00420719` - Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)	N/A
Completed	`NCT02936635` - A Study for Patients Who Completed VITALITY-ALS (CY 4031)	Phase 3
Withdrawn	`NCT04055532` - Biomarkers in Neurodegenerative Diseases
Completed	`NCT03645031` - Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease	N/A
Completed	`NCT01786603` - Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)	Phase 2
Completed	`NCT02559869` - Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
Completed	`NCT01592552` - A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
Completed	`NCT00403104` - Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)	Phase 2
Recruiting	`NCT02424669` - Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients	N/A
Completed	`NCT01366027` - PRISM Registry: Pseudobulbar Affect Registry Series	N/A
Completed	`NCT00330681` - Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)	Phase 3
Completed	`NCT00876772` - Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)	Phase 2/Phase 3
Not yet recruiting	`NCT06351592` - First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS — NurOwn

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms